CSNK1A1 and myeloid neoplasm: For instance, lenalidomide degrades casein kinase 1 alpha (CK1α, encoded by CSNK1A1 gene) more efficiently than thalidomide and pomalidomide in myeloid neoplasms, thus providing a therapeutic window for lenalidomide in del (5q) MDS, where CSNK1A1 haploinsufficiency due to genetic deletion sensitizes tumor cells to lenalidomide (80, 186, 187).